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Abstract
Recently, a new family of facilitative carriers has been cloned consisting of the reduced folate (SLC19A1) and the thiamine
(SLC19A2) transporters. Despite a high level of sequence identity and similarity there is essentially no functional overlap
between these carriers. The former transports folates and the latter thiamine. In this paper we describe the function of
SLC19A3, another member of this transporter family most recently cloned, after transient transfection of the cDNA into
HeLa cells. Uptake of [3H]thiamine, but not of methotrexate nor folic acid, was enhanced in SLC19A3 transfectants relative
to vector control. Similarly, in the transfectants thiamine transport increased with an increase in pH with peak activity at pH
V7.5. While [3H]thiamine uptake was markedly inhibited by nonlabeled thiamine it was not inhibited by several organic
cations in 100-fold excess. Hence this carrier has a high degree of specificity for vitamin B1. The data indicate that SLC19A3
has the characteristics of SLC19A2 (ThTr1) and represents a second thiamine transporter (ThTr2) in this family of
facilitative carriers. ß 2001 Elsevier Science B.V. All rights reserved.
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Recently, a new family of facilitative carriers has
been identi¢ed consisting of the reduced folate car-
rier (SLC19A1) cloned in 1995 [1^5] and a thiamine
carrier (SLC19A2) cloned in 1999 [6^9]. The human
proteins have a sequence identity of 40% and simi-
larity of 55% [8]. However, despite the high degree of
structural similarity of these proteins there is essen-
tially no functional overlap. The reduced folate car-
rier (RFC1) does not transport thiamine and the thi-
amine carrier, ThTr1, does not transport reduced or
oxidized folates [10]. This is consistent with the sub-
stantial structural di¡erences between these com-
pounds and the fact that folates are anions (RFC1
is an anion exchanger [11]), and thiamine a cation at
physiological pH. Most recently, another transporter
with high homology to these carriers has been iden-
ti¢ed, SLC19A3 [12]. The human gene encodes a
protein with a predicted molecular mass of V56
kDa with 39% sequence identity to RFC1 and 48%
identity with ThTr1. The mouse protein is 41% iden-
tical to RFC1 and 58% identical to ThTr1. This,
along with the Clustal V phylogenetic analyses, indi-
cates that SLC19A3 is more closely related to
SLC19A2 than RFC1 [12]. We report here on studies
that assess the function of SLC19A3 in HeLa cells
transiently transfected with this gene. These studies
demonstrate that similar to ThTr1, SLC19A3 is a
thiamine transporter without folate transport activ-
ity.
HeLa cells (American Type Collection, Manassas,
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VA, USA) were cultured in Dulbecco’s modi¢ed Ea-
gle’s medium (DMEM) containing 4 mM L-gluta-
mine, 4.5 g/l glucose, penicillin (100 U/ml), strepto-
mycin (100 Wg/ml), and 10% fetal bovine serum
(Gibco BRL). Cells were grown at the bottom of
10 ml glass vials (Research Product International)
as previously reported [13]. Transient transfection
was achieved using Lipofectamine Plus (Gibco
BRL) according to the manufacturer’s protocol. Up-
take of [3H]thiamine was measured as previously de-
scribed in adherent cells in the glass vials [13]. Ex-
periments at pH 5.0^6.5 were performed in MBS (20
mM MES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl2,
5 mM glucose). Experiments at pH 7.0^8.0 utilized
an HBS bu¡er (20 mM HEPES 140 mM NaCl, 5 mM
KCl, 2 mM MgCl2, 5 mM glucose). Radiolabeled
compounds (Amersham) were: [3H]thiamine,
[3P,5P,7P-3H]methotrexate, and [3P,5P,7P,9-3H]folic
acid. All other reagents were obtained in highest pu-
rity available from various commercial sources.
Human SLC19A3 cDNA was cloned by RT-PCR.
First strand cDNA was synthesized by reverse tran-
scriptase (Superscript II RT, Gibco BRL) and oli-
go(dT). SLC19A3 cDNA was ampli¢ed using speci¢c
primers. The primer pairs used were as follows:
FP1: 5P-TCGGGATCCTTGGTGAACAGACACT-
3P, and RP2: 5P-TCGGAATTCCAAGTTCCACTG-
TTGC-3P.
PCR ampli¢cation was carried out with pfu Turbo
(Clontech). The PCR cycle for ampli¢cation encom-
passed initial denaturation at 95‡C for 3 min fol-
lowed by 30 cycles at 95‡C for 1 min, annealing at
55‡C for 1 min and elongation at 72‡C for 2 min.
The ¢nal extension was performed at 72‡C for 10
min. The 1.8 kb ampli¢ed PCR fragment was cloned
in the pcDNA3.1(+) (Invitrogen) expression vector
at BamHI-EcoRI sites.
Northern blot hybridization was carried out using
total RNA from the transiently transfected HeLa
cells. The RNA samples were size-fractionated on a
denaturing formaldehyde-agarose gel and probed
with 32P labeled human SLC19A3 cDNA.
Human SLC19A3 cDNA was cloned from human
kidney total RNA by RT-PCR and transiently trans-
fected into HeLa cells. Fig. 1 is a Northern blot that
demonstrates high level expression of SLC19A3 in
the cDNA transfected HeLa cells. No message was
detected in the vector-only transfected cells consis-
tent with a low level of endogenous expression.
Fig. 2 illustrates that uptake of [3H]thiamine (1 WM)
was increased V3.5-fold in the SLC19A3 transfected
cells as compared to the vector-only transfectant but
there was no change in in£ux of equimolar metho-
trexate or folic acid. The pH pro¢le of thiamine up-
take mediated by SLC19A3 (Fig. 3) was similar to
that reported for ThTr1 [6]. Peak transport activity
was pH V7.4 and in£ux at this pH was V3.5-fold
higher than at pH 5.0. Increasing pH beyond 7.4
decreased the activity. In the vector-only transfected
Fig. 1. Expression of ThTr2. Northern blot analysis of transi-
ently transfected HeLa cells. Lane 1, HeLa cells were transi-
ently transfected with ThTr2 cDNA. Lane 2, HeLa cells transi-
ently transfected with the pcDNA 3.1(+) vector alone. Twenty
micrograms of total RNA were loaded per lane. Full length
ThTr2 cDNA was used as the template for the random primer
labeling and subsequently used as probe for the Northern anal-
ysis.
Fig. 2. Functional activity of ThTr2. HeLa cells transiently
transfected with ThTr2 cDNA were assessed for transport activ-
ity. Uptake was measured over 2 min as described in the text
with 1 WM of [3H]thiamine, [3H]methotrexate or [3H]folic acid.
Results are the averages of three separate experiments þ S.E.M.
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HeLa cells the highest thiamine uptake activity was
also at pH V7.4 re£ecting the properties of the en-
dogenous transport process(es). Thiamine is an or-
ganic cation but this transport system does not
have signi¢cant a⁄nity for other organic cations
since neither 100 WM choline chloride, cimetidine,
nor tetraethylammonium bromide inhibited in£ux
of 1 WM [3H]thiamine. Two other B vitamins, pyri-
doxine (a cation) and niacin (a zwitterion), whose
speci¢c transporters are not as yet identi¢ed [14,15]
also did not inhibit [3H]thiamine uptake. On the oth-
er hand, 100 WM nonlabeled thiamine inhibited ra-
diotracer uptake by 95% under these conditions (Fig.
4). These data demonstrate the high degree of spec-
i¢city of this carrier for thiamine. This is unlike a
number of other carriers that accept a variety of
organic cations as substrates [16].
These studies are consistent with the conclusion
that SLC19A3 is a second thiamine transporter (to
be termed ThTr2) that, like SLC19A2, has high se-
quence identity with RFC1 but essentially no func-
tional overlap. ThTr1 has been cloned by several
groups [6^9] and identi¢ed as the locus of the genetic
defect associated with thiamine-responsive megalo-
blastic anemia (TRMA). Mutations in the ThTr1
gene have been shown to be the cause of the defect
in transporter function in this syndrome [7]. Of par-
ticular interest is that while TRMA patients manifest
diabetes, deafness and megaloblastic anemia, they
usually do not exhibit other neurological or cardiac
signs of thiamine de¢ciency [17]. Further, these pa-
tients have normal thiamine blood levels [18]. These
observations suggest that there must be other
route(s) by which thiamine is transported in human
cells [17]. ThTr1 is widely expressed in human tissues
but is most abundant in skeletal muscle, followed by
heart, placenta, kidney and liver [6^9]. ThTr2 is also
expressed in many human tissues but is most abun-
dant in placenta followed by liver, kidney and heart
[12]. The pattern of expression of ThTr2 relative to
ThTr1 may account for the sparing of thiamine-de-
pendent tissues under conditions in which thiamine
transport mediated by ThTr1 is impaired, as in
TRMA. It will be important to clarify the speci¢c
location of these transporters in enterocytes and their
role in intestinal absorption of thiamine [19], in par-
ticular the vectorial £ows of thiamine across the
apical brush border and basolateral membranes.
Clearly, further understanding of the role of these
two thiamine transporters in various human tissues
will await the development of antibodies that will
permit assessment of protein expression and localiza-
tion.
Finally, there is another potential route for trans-
port of thiamine into human cells, RFC1. Studies
from this laboratory have demonstrated that whereas
thiamine is not a substrate for RFC1, thiamine py-
Fig. 3. pH pro¢le of ThTr2 activity. Uptake of 1 WM
[3H]thiamine over 2 min was assessed in transiently transfected
HeLa cells at the indicated pH. Results are averages of three
separate experiments þ S.E.M.
Fig. 4. Speci¢city of ThTr2 uptake. Uptake of 1 WM
[3H]thiamine over 2 min was assessed in the presence of 100
WM nonlabeled organic cations or niacin in transiently trans-
fected HeLa cells. Thiamine uptake in the absence of a compet-
itor was the control. ThTr2 speci¢c uptake in each case was
calculated by subtracting the endogenous thiamine (transport of
thiamine in vector-only transfected cells) uptake from the total
uptake. Transport activity is expressed as the percentage of
control. The results are averages of three separate experiments
þ S.E.M.
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rophosphate is a relatively good substrate [10]. While
thiamine pyrophosphate is found almost exclusively
in cells where it is synthesized by thiamine pyrophos-
phokinase, the monophosphate is present in the
blood of man at levels nearly comparable to thiamine
[20]. Hence, in cells in which transport mediated by
the thiamine carriers is impaired, or these carrier are
not normally expressed, RFC1 is a potentially impor-
tant alternative pathway by which cells can meet
their metabolic needs for vitamin B1.
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